Seoul Semiconductor Files Patent Litigation for Infringement of 12 Acrich Patents
Seoul Semiconductor Co., Ltd. announced on September 19, 2017 that it has filed a patent infringement lawsuit, together with its affiliate, Seoul Viosys Co., Ltd., against Archipelago Lighting, Inc. in the U.S. District Court for the Central District of California.
In its complaint, Seoul asserts that Archipelago Lighting is selling various LED bulb products, including filament LED bulbs, that infringe on “twelve” (12) patents covering aspects of Seoul’s long-established Acrich technology. These Acrich patents include fundamental LED technologies, such as LED driver technology for high-voltage operation, MJT (Multi-Junction Technology), filament LED bulb structure, LED packaging, LED epitaxial growth, LED chip fabrication, etc.
In conventional LED products, one LED unit usually operates at a low voltage (3V) and high current. In order to increase brightness, one must connect many LED units through wire-bonding, but this can lead to other issues, such as an oversized, costly operating circuit, a substantial increase in manufacturing costs and defects caused by multiple wire-bonding connections.
Seoul’s Acrich technology resolves such problems by enabling the design of a high-voltage product with a high power output that relies on only a small number of LED units. Acrich technology does so by utilizing its innovative LED driver technology to enable high-voltage operation, as well as its unique MJT technology for mounting and integrating many LEDs within a small area. Seoul’s Acrich technology enables LED products to operate using AC power without requiring conversion to DC, minimizing power dissipation and reducing overall component count. This maximises the available space in LED products, facilitating a simple circuit design and significantly reducing the size and cost of LED products.
Acrich technology has become widely adopted not only in general lighting but also in electrical products and automotive lighting.
For example, in the general lighting market, 12V/18V high-voltage products have become increasingly popular, and there has been a significant increase in the demand for 36V/48V products. To manufacture such high-voltage products, Acrich technology is necessary to support LED driver technology for high-voltage operations with MJT technology. The innovative benefits of Acrich technology have resulted in its being applied in street lights and commercial lights in countries throughout the world, including locations as diverse as Korea, the United States, China, Europe, Southeast Asia, Mongolia and Kazakhstan.
In electronic products, Acrich technology is being increasingly used for valuable product lines such as large-area television displays. Acrich technology enables a dramatic enhancement in the service life and efficiency of such displays by simplifying their internal system. It also dramatically reduces the size and thickness of the final product, rendering it more pleasing to consumers, by reducing the amount of internal space previously reserved for complicated electric circuits. In particular, Acrich enables full-array local dimming that enhances the contrast range of the latest ultra-thin UHD display products by providing the next generation of backlighting solutions for high-definition displays.
Acrich technology is also expanding its application to other product areas that require high LED light output, such as landscape lighting, vehicle headlamps and day driving lights as well as mobile phone flashes.
Seoul began to develop its unique Acrich technology in the mid 1990s and has continued to launch advanced, innovative Acrich products every year following its successful mass production in 2005. Based on its decades of investment in research and development, Seoul has established a large patent portfolio for Acrich technology, including rights to approximately 1,000 Acrich patents. However, with the recent increase in the demand for high-voltage LED products, several companies have begun to manufacture products that infringe on Seoul’s Acrich patents. In order to protect its hard-earned investment against such infringement, Seoul will actively enforce its patent rights against any infringers.
Dr. Ki-bum Nam, Head of Seoul’s R&D Center and Chief Technology Officer said: “We have extensively investigated copycat products infringing on Acrich technology with various LED TVs, general lighting and automotive lighting products. In order to protect Acrich technology, which has been developed with considerable resources over many decades, we will continuously take any and all legal action against infringers that disregard our valuable intellectual property.” Nam added: “Creating a fair market that respects intellectual property is important for all innovative entrepreneurs and businesses.”
Related press photos are available here: http://wbn-hamburg.net/cloud/public.php?service=files&t=f5a6a3d06bf01d3cb7b5b2c837abb9c3
About Seoul Semiconductor:
Seoul Semiconductor develops and commercializes light emitting diodes (LEDs) for automotive, general illumination, specialty lighting, and backlighting markets. As the fourth-largest LED manufacturer globally, Seoul Semiconductor holds more than 12,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; Wicop – a simpler structured package-free LED which provides market leading color uniformity, cost savings at the fixture level with high lumen density and allows design flexibility; NanoDriver Series –World’s Smallest 24W DC LED Drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, includes all AC LED-related technologies from chip to module and circuit fabrication, as well as multi-junction technology (MJT); and nPola, a new LED product based on GaN-substrate technology that achieves over ten times the output of conventional LEDs. For more information about Seoul Semiconductor, please visit http://www.seoulsemicon.com
Wicop and Acrich are trademarks of Seoul Semiconductor Co., Ltd.
Seoul Semiconductor Co., Ltd
Jake Jung, +82 070.4391.8270
Seoul Semiconductor Europe GmbH
Ariane Heim, +49 (0)89 450 3690-0
Seoul Semiconductor Inc.
David Cox, +1 (919) 410-9856
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 21:28 | Tiedote
Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (http://www.elektroniknet.de), a leading German electronics publication. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005646/en/ Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl
Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 19:05 | Tiedote
Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 15:52 | Tiedote
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 15:50 | Tiedote
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 15:46 | Tiedote
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c
Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 15:00 | Tiedote
Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at www.aitheon.com/news) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005269/en/ Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme